Sean Harper, executive vice president of research and development at Amgen (NASDAQ: [[ticker:AMGN]]), is retiring in order to pursue work in the early-stage biotech community. The Thousand Oaks, CA, drug maker promoted David Reese, senior vice president of translational sciences and oncology, to Harper’s former role. Harper will stay with the company for an unspecified … Continue reading “Amgen Executives Sean Harper, Anthony Hooper Set to Retire”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
Achaogen R&D Head Hillan, Two Other Execs to Depart in Restructuring
Kenneth Hillan, president of research and development for antibiotics developer Achaogen (NASDAQ: [[ticker:AKAO]]), is one of three executives leaving the company as part of a corporate restructuring that is reducing headcount by 28 percent. South San Francisco, CA-based Achaogen announced the changes in advance of the company’s launch of plazomicin (Zemdri), a treatment for complicated … Continue reading “Achaogen R&D Head Hillan, Two Other Execs to Depart in Restructuring”
Achaogen Restructures, Slashes Staff 28% as Antibiotic Launches
[Story updated 7/27/18, 7:07 p.m. EDT. See below.] The runup to a new drug launch is usually a time for hiring, but as Achaogen commercializes its new drug, the antibiotics developer is doing just the opposite. Faced with a tough market for antibacterial products, Achaogen (NASDAQ: [[ticker:AKAO]]) announced Thursday that it will eliminate 80 positions, … Continue reading “Achaogen Restructures, Slashes Staff 28% as Antibiotic Launches”
Gilead Sciences CEO Milligan to Depart for “New Opportunities”
John Milligan will step down as president and CEO of Gilead Sciences (NASDAQ: [[ticker:GILD]]) at the end of the year, the Foster City, CA company announced Wednesday. Milligan’s departure will end a 28-year career with the company. In a prepared statement, Milligan said he would move on to “new and different opportunities.” Milligan will also … Continue reading “Gilead Sciences CEO Milligan to Depart for “New Opportunities””
Vertex Exec Saltarelli Joins Syntimmune as Chief Medical Officer
Mario Saltarelli has been appointed chief medical officer of Boston-based Syntimmune. Saltarelli comes to Syntimmune from Vertex (NASDAQ: [[ticker:VRTX]]), where he was senior vice president of early development and neurology. Donald Johns, who has been acting chief medical officer of Syntimmune, will now become executive vice president of medical and scientific affairs. Syntimmune is developing … Continue reading “Vertex Exec Saltarelli Joins Syntimmune as Chief Medical Officer”
Eisai & Biogen Reveal Promising Alzheimer’s Data, But Questions Linger
Data from six additional months of treatment with an experimental drug for Alzheimer’s disease were enough to turn a failed mid-stage clinical trial into a possible success. On Wednesday, the Japanese pharmaceutical company Eisai and its U.S.-based partner, Biogen, explained how, providing details that point to ways that their drug, unlike many before it, might … Continue reading “Eisai & Biogen Reveal Promising Alzheimer’s Data, But Questions Linger”
Soil Health Startup Cool Planet Adds $20M for New Manufacturing Site
Cool Planet, an agricultural technology startup focused on improving the quality of soil, has raised an additional $20.3 million to finance construction of a manufacturing facility. Greenwood Village, CO-based Cool Planet said the new capital is an extension of the company’s 2017 $19.3 million Series A round of investment. The latest capital infusion was led … Continue reading “Soil Health Startup Cool Planet Adds $20M for New Manufacturing Site”
Nabriva Bolsters Antibiotics Pipeline with Zavante Acquisition
Nabriva Therapeutics has acquired Zavante Therapeutics in a stock deal that brings to the antibiotics developer an FDA-ready drug. Under the deal terms announced after the market close Tuesday, San Diego-based Zavante received an upfront payment of 8.2 million Nabriva (NASDAQ: [[ticker:NBRV]]) shares. Nabriva, which splits its operations between Ireland and King of Prussia, PA, … Continue reading “Nabriva Bolsters Antibiotics Pipeline with Zavante Acquisition”
Bristol-Myers Squibb Executive Murdo Gordon Set to Depart
Murdo Gordon, chief commercial officer of Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), is leaving. The New York-based pharmaceutical giant announced Monday that Gordon would depart on Aug. 3 “to pursue another opportunity.” No other details were given. According to a securities filing, Gordon notified the company of his plans on July 17. Before starting as Bristol’s chief … Continue reading “Bristol-Myers Squibb Executive Murdo Gordon Set to Depart”
Crinetics Pharma Appoints Alan Krasner Chief Medical Officer
Alan Krasner has joined Crinetics Pharmaceuticals (NASDAQ: [[ticker:CRNX]]) as chief medical officer. Krasner comes to the San Diego biotech from Shire (NASDAQ: [[ticker:SHPG]]), where he was a senior medical director. His experience also includes posts at Biodel and Pfizer (NYSE: [[ticker:PFE]]). Crinetics develops treatments for rare endocrine diseases and endocrine-related tumors.
Agios Pharma’s Drug for Rare Blood Cancer Wins Speedy FDA Nod
An Agios Pharmaceuticals drug developed to treat a rare form of leukemia has received FDA approval ahead of schedule. This marks the second time in the past year that the company has won the regulatory nod for a treatment for the disease, but this is the first approved drug that’s wholly owned by the Cambridge, … Continue reading “Agios Pharma’s Drug for Rare Blood Cancer Wins Speedy FDA Nod”
PTC Dives Into Gene Therapy with $50M Agilis Biotherapeutics Deal
PTC Therapeutics is looking to gene therapy in a bid to broaden its pipeline, scooping up privately held Agilis Biotherapeutics in a cash and stock deal. South Plainfield, NJ-based PTC (NASDAQ: [[ticker:PTCT]]) will pay $50 million up front, plus $150 million in PTC shares, for Agilis. Agilis, based in Cambridge, MA, could get up to … Continue reading “PTC Dives Into Gene Therapy with $50M Agilis Biotherapeutics Deal”
FDA Puts Mersana Cancer Study on Partial Hold After Patient Death
[Updated, 7/19/18, 6:25 p.m. See below.] A patient has died in a clinical trial testing Mersana Therapeutics’ lead cancer drug, and the FDA has put a partial hold on the early-stage study as a result. The partial hold means that no new patients will be enrolled in the Phase 1 clinical trial. But patients who … Continue reading “FDA Puts Mersana Cancer Study on Partial Hold After Patient Death”
Fresh Off Bristol Buyout, IFM Backers Raise $31M to Plot a Second Strike
Nearly one year ago, biotech startup IFM Therapeutics sold some of its assets to Bristol-Myers Squibb for $300 million. But IFM’s founders stuck around to try to capitalize on the startup’s remaining research. They’ve formed a Boston business, IFM Tre, that has just raised $31 million to fund some of that work. The cash comes … Continue reading “Fresh Off Bristol Buyout, IFM Backers Raise $31M to Plot a Second Strike”
Juno’s Fontenot Joins Immusoft as Chief Scientific Officer
Jason Fontenot has been appointed chief scientific officer of Seattle cell therapy developer Immusoft. Fontenot most recently worked at Seattle cancer immunotherapy company Juno Therapeutics, which was acquired by Celgene (NASDAQ: [[ticker:CELG]]) earlier this year in a $9 billion deal. Immusoft is researching a way of reengineering the B cells of the body into treatments for … Continue reading “Juno’s Fontenot Joins Immusoft as Chief Scientific Officer”
Corindus Vascular Promotes Douglas Teany to Chief Operating Officer
Douglas Teany has taken on a new role at Corindus Vascular Robotics (NYSE American: [[ticker:CVRS]]) as the Waltham, MA, company’s chief operating officer. Since 2016, he had served as Corindus’ senior vice president of R&D and operations. Corindus has commercialized the CorPath System, an FDA-cleared medical device that uses robotics technology in vascular procedures.
Rubius Upsizes IPO and Hauls in $241M for Red Blood Cell Therapies
Rubius Therapeutics has joined the parade of biotech companies going public, raising a whopping $241.1 million to support its approach of engineering red blood cells into off-the-shelf treatments for disease. Late Tuesday night, Cambridge, MA-based Rubius priced its offering of 10.4 million shares at $23 apiece. The company had initially planned to sell 9.5 million … Continue reading “Rubius Upsizes IPO and Hauls in $241M for Red Blood Cell Therapies”
Inari Agriculture Sprouts with Plans to Gene Edit “Personalized Seeds”
The seeds farmers plant in their fields can carry certain desirable traits, such as drought tolerance or pest resistance. Breeding or genetic engineering can produce such traits, but ag biotech startup Inari Agriculture aims to take trait development to a new level—customizing seeds to grow best in the soil and weather at the farm where … Continue reading “Inari Agriculture Sprouts with Plans to Gene Edit “Personalized Seeds””
With $45M, HotSpot Takes Drug Research to New Biological Real Estate
In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines. HotSpot is now emerging from stealth with preclinical compounds that could become new treatments … Continue reading “With $45M, HotSpot Takes Drug Research to New Biological Real Estate”
Pliant Picks Up $62M to Test Lung, Liver Fibrosis Drug in the Clinic
The cause of fibrosis, the hardening and thickening of connective tissue in organs, isn’t known and it has few treatments. Pliant Therapeutics aims to bring patients who have this chronic and life-threatening condition in the lungs or the liver a new treatment option—and it now has $62 million to test its lead drug in humans. … Continue reading “Pliant Picks Up $62M to Test Lung, Liver Fibrosis Drug in the Clinic”
With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug
More than a year after the FDA rejected Amgen’s experimental osteoporosis drug due to safety concerns, the Thousand Oaks, CA, company has teed up a new application. The Amgen (NASDAQ: [[ticker:AMGN]]) drug, romosozumab (Evenity), is an antibody treatment meant to strengthen bones and reduce the chance that they could break. But while romosozumab did lower … Continue reading “With New Data, Amgen Tries Again for FDA OK of Osteoporosis Drug”
Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More
Drug price changes typically happen either at the start of the calendar year or the beginning of the third quarter. Such changes are routine for many companies, but Pfizer took an unusual step this week by rolling back scheduled price increases on 40 of its drugs. The change of plan happened after Pfizer (NYSE: [[ticker:PFE]]) … Continue reading “Bio Roundup: Pfizer’s Prices, Novartis Cuts, Gene Therapy Guide & More”
Otsuka Ramps Up Its Antibody Game with $430M Visterra Acquisition
Otsuka Pharmaceutical is expanding its pipeline and U.S. reach with an agreement to acquire Waltham, MA, clinical-stage drug developer Visterra for $430 million in cash. The deal, announced Wednesday, comes nine months after Visterra closed a $46.7 million Series C round to finance clinical development of its antibody drug programs. That financing followed Visterra’s attempt … Continue reading “Otsuka Ramps Up Its Antibody Game with $430M Visterra Acquisition”
BioCryst Drops Idera Pharma Merger After Shareholders Veto Deal
BioCryst Pharmaceuticals is ending a plan to merge with Idera Pharmaceuticals and form a single company focused on rare diseases. Durham, NC-based BioCryst (NASDAQ: [[ticker:BCRX]]) terminated the merger agreement on Tuesday following a meeting that saw shareholders vote overwhelmingly against the proposal. Of the more than 80 million shares represented in the vote, 50.6 million … Continue reading “BioCryst Drops Idera Pharma Merger After Shareholders Veto Deal”
Former Celgene Exec Golumbeski Joins Grail as President
Grail has appointed George Golumbeski to serve as president of the Menlo Park, CA, cancer test developer. He has also joined Grail’s board of directors. Golumbeski was most recently executive vice president of business development at Celgene (NYSE: [[ticker:CELG]]). In May, Grail closed a $300 million Series C round of financing to continue its work … Continue reading “Former Celgene Exec Golumbeski Joins Grail as President”
Acceleron Pharma Appoints Robert Zeldin Chief Medical Officer
Robert Zeldin has been appointed chief medical officer of Cambridge, MA, drug developer Acceleron Pharma (NASDAQ: [[ticker:XLRN]]). Zeldin joins Acceleron from Belgium-based Ablynx, where he was chief medical officer. Zeldin’s appointment comes as Acceleron and partner Celgene (NASDAQ: [[ticker:CELG]]) prepare to file for FDA approval of the drug luspatercept. The companies have released positive results … Continue reading “Acceleron Pharma Appoints Robert Zeldin Chief Medical Officer”
Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder
A drug from Celgene and Acceleron Pharma has met the main goals of a late-stage test as a treatment for a rare blood disorder, the second set of positive results that the partners have released for the drug in as many weeks. The latest announcement covered use of the drug, luspatercept, as a treatment for … Continue reading “Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder”
CTI BioPharma’s Non-Hodgkin Lymphoma Drug Fails Study, Shares Sink
A CTI BioPharma treatment for a form of non-Hodgkin lymphoma has failed a clinical trial key for maintaining its approval in Europe, casting doubt on the drug’s prospects with the FDA. Seattle-based CTI (NASDAQ: [[ticker:CTIC]]) said Monday that its drug, pixantrone, failed to meet the goal of improving progression-free survival, which is the length of … Continue reading “CTI BioPharma’s Non-Hodgkin Lymphoma Drug Fails Study, Shares Sink”
Biogen, Eisai Claim Success in New Analysis of Failed Alzheimer’s Study
Biogen and Eisai are reporting encouraging data from a mid-stage study in Alzheimer’s disease, reviving hopes for a drug and an approach to treating the disease that many had declared a failure. The drug, BAN2401, had in fact failed in clinical studies. Last December, Biogen (NASDAQ: [[ticker:BIIB]]) and Eisai reported that the drug did not … Continue reading “Biogen, Eisai Claim Success in New Analysis of Failed Alzheimer’s Study”
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
Boston Scientific is adding on to its heart rhythm management business again, this time with a deal to acquire atrial fibrillation device startup Cryterion Medical for $202 million. The cash payment covers the 65 percent of Cryterion that the Marlborough, MA, medical device giant does not already own. Boston Scientific (NYSE: [[ticker:BSX]]) had been an … Continue reading “Boston Scientific Continues M&A Streak with $202M Deal for Cryterion”
Twist Bioscience Appoints Aaron Sato Chief Scientific Officer
Twist Bioscience has appointed Aaron Sato chief scientific officer of pharma, and vice president of protein engineering. Before joining the San Francisco-based company, Sato was chief scientific officer of LakePharma. In other moves, Jim Thorburn was named chief financial officer. Thorburn was most recently chief sales officer of Televerde. Twist makes synthetic DNA for companies … Continue reading “Twist Bioscience Appoints Aaron Sato Chief Scientific Officer”
Priority Changes for Novartis Spell the End for Aveo Pharma Alliance
When Aveo Pharmaceuticals found itself floundering three years ago in the wake of the FDA’s rejection of its lead cancer drug, Novartis threw out a lifeline: a partnership on another Aveo drug that would finance its development. Now Novartis is pulling that support away. Novartis (NYSE: [[ticker:NVS]]) is ending the partnership on the compound AV-380, … Continue reading “Priority Changes for Novartis Spell the End for Aveo Pharma Alliance”
Sanofi’s Andre Turenne Is Slated to Become Voyager Therapeutics CEO
Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]) has appointed Andre Turenne to serve as president and CEO of the Cambridge, MA-based gene therapy developer. Turenne will succeed Steven Paul, who is retiring but will remain on Voyager’s board of directors. Turenne comes to Voyager from Sanofi (NYSE: [[ticker:SNY]]), where he was most recently senior vice president, global head, … Continue reading “Sanofi’s Andre Turenne Is Slated to Become Voyager Therapeutics CEO”
Adicet Bio Appoints Stewart Abbot Chief Scientific Officer
Stewart Abbot has been appointed chief scientific officer of Adicet Bio. Before coming to the Menlo Park, CA-based company, Abbot was chief development officer at Fate Therapeutics (NASDAQ: [[ticker:FATE]]) in La Jolla, CA. Adicet launched in 2016 backed by a $51 million Series A round of financing to develop “off-the-shelf” immune cell therapies for cancer … Continue reading “Adicet Bio Appoints Stewart Abbot Chief Scientific Officer”
Nanotech Liquidia Hops IPO Wave as Lead Drug Faces Late-Stage Test
Liquidia Technologies focuses on the small. Its method of producing nano-scale particles improves how a drug reaches its target in the body. Now the clinical-stage biopharmaceutical company is aiming for something big: an IPO to finance tests of a pair of drugs that use this drug delivery technology. Research Triangle Park, NC-based Liquidia filed the … Continue reading “Nanotech Liquidia Hops IPO Wave as Lead Drug Faces Late-Stage Test”
Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing
An experimental Acceleron drug for a blood disorder has hit the main goals of a pivotal study, and the company and partner Celgene say they now plan to file for FDA approval next year. The Acceleron (NASDAQ: [[ticker:XLRN]]) drug, luspatercept, is being tested as a treatment for myelodysplastic syndrome (MDS), a type of cancer characterized … Continue reading “Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing”
SutroVax’s Alan Kimura Joins Enzyvant as Chief Medical Officer
Alan Kimura has been appointed chief medical officer of Cambridge, MA-based Enzyvant. Before joining Enzyvant, Kimura was chief medical officer of Foster City, CA-based SutroVax. His experience also includes posts at Shire (NASDAQ:[[ticker:SHPG]]), Novartis Vaccines, and Translate Bio (NASDAQ: [[ticker:TBIO]]). Enzyvant is the rare disease subsidiary of Switzerland-based Roivant Sciences. The company is preparing to … Continue reading “SutroVax’s Alan Kimura Joins Enzyvant as Chief Medical Officer”
Deciphera Pharma Appoints Stephen Ruddy Chief Technical Officer
Stephen Ruddy has been appointed chief technical officer of Waltham, MA-based Deciphera Pharmaceuticals (NASDAQ: [[ticker:DCPH]]). Before joining Deciphera, Ruddy was vice president of pharmaceutical development at Tesaro (NASDAQ: [[ticker:TSRO]]), also based in Waltham. Last year, Deciphera raised $128 million in an IPO to finance clinical testing of its cancer drug DCC-2618 in patients who have … Continue reading “Deciphera Pharma Appoints Stephen Ruddy Chief Technical Officer”
IPO Wave Rolls On as Five Life Science Firms Haul In $651M
A week after seven biotechs went public, setting a new record for the Nasdaq, five more life sciences companies have joined the club. The latest crop continued the positive momentum for life sciences offerings, as the group either met or exceeded their projections and raised a total of $651 million. Neon Therapeutics (NASDAQ: [[ticker:NTGN]]) was … Continue reading “IPO Wave Rolls On as Five Life Science Firms Haul In $651M”
Precision Bio Lands $110M as Gene-Edited Cell Therapy Nears Clinic
While CRISPR has grabbed the lion’s share of gene-editing headlines, Precision BioSciences has used its own gene-editing technology to quietly build a pipeline of products for both agriculture and human health. The Durham, NC company is now preparing to start testing a gene-edited cell therapy for cancer in humans and it has raised $110 million … Continue reading “Precision Bio Lands $110M as Gene-Edited Cell Therapy Nears Clinic”
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
An experimental treatment for Duchenne muscular dystrophy has failed a mid-stage study, and Summit Therapeutics said Wednesday it is now stopping work on the drug. Summit shares plunged nearly 80 percent on the news. Duchenne is an inherited disorder found mainly in boys that causes progressive muscle weakness. The Summit (NASDAQ: [[ticker:SMMT]]) drug, ezutromid, was … Continue reading “Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure”
Cibus Raises $70M for Marketing of Gene-Edited Canola, More R&D
Sales of Cibus’ first product, a gene-edited canola, have gone so well that the San Diego company has raised $70 million in new financing to boost its commercialization efforts. The Series C round of funding announced Tuesday was led by Fidelity Management and Research Company, and was joined by Alexandria Venture Investments, Cormorant Asset Management, … Continue reading “Cibus Raises $70M for Marketing of Gene-Edited Canola, More R&D”
Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come
When President Trump signed legislation last month allowing seriously ill patients the “right to try” unapproved drugs without FDA oversight, he voiced a bold prediction: Within two weeks, he said, drug companies would announce “voluntary massive drops in prices.” Asked for further detail, the Department of Health and Human Services (HHS) declined to elaborate on … Continue reading “Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come”
Bio-Techne to Acquire Liquid Biopsy Firm Exosome Diagnostics for $250M
Exosome Diagnostics, a company that has developed technology to test for disease by analyzing blood and other bodily fluids, has agreed to be acquired by Bio-Techne in a $250 million cash deal. If Waltham, MA-based Exosome hits certain unspecified milestones, the company could receive up to $325 million more, the companies announced Monday after the … Continue reading “Bio-Techne to Acquire Liquid Biopsy Firm Exosome Diagnostics for $250M”
Humacyte Promotes Jeffrey Lawson to Chief Executive
Jeffrey Lawson has been appointed CEO of regenerative medicine company Humacyte. Lawson had been chief medical officer of the Research Triangle Park, NC, company since 2015. Lawson’s experience includes several roles at Duke University Medical Center. Former CEO Carrie Cox has taken on the role of executive chairman. Humacyte has developed a way to grow … Continue reading “Humacyte Promotes Jeffrey Lawson to Chief Executive”
Finch Therapeutics Names Ulrich Thienel Chief Medical Officer
Ulrich Theinel has been appointed chief medical officer of Finch Therapeutics. Before joining the Somerville, MA, microbiome therapeutics developer, Theinel held leadership positions at Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies. Finch is currently in mid-stage clinical studies testing its microbial therapy as a treatment for Clostridium difficile infection. In other moves, Finch … Continue reading “Finch Therapeutics Names Ulrich Thienel Chief Medical Officer”
Akero Closes $65M Financing to Back Liver Drug Licensed from Amgen
New biotech startup Akero Therapeutics debuted Monday with $65 million in a Series A round of funding to advance clinical development of a drug for the fatty liver disease nonalcoholic steatohepatitis (NASH). Cambridge, MA-based Akero licensed the drug from Amgen (NASDAQ: [[ticker:AMGN]]), which had tested it in Phase 1 studies. Akero said Monday it will … Continue reading “Akero Closes $65M Financing to Back Liver Drug Licensed from Amgen”
Evofem’s David Friend Appointed Daré Bio Chief Scientific Officer
David Friend has been appointed chief scientific officer of San Diego-based Daré Biosciences (NASDAQ: [[ticker:DARE]]). Friend comes to Daré from another San Diego biotech company, Evofem Biosciences (NASDAQ: [[ticker:EVFM]]), where he was chief scientific officer. Daré develops treatments focusing on women’s reproductive health. The company gained its public stock listing last year through a reverse … Continue reading “Evofem’s David Friend Appointed Daré Bio Chief Scientific Officer”
Gemini Therapeutics Names Sandra Rojas-Caro Chief Medical Officer
Sandra Rojas-Caro has been appointed chief medical officer of Cambridge, MA-based Gemini Therapeutics. She was most recently chief medical officer for Aeglea BioTherapeutics. In other moves, Gemini named Claude Knopf to the position of chief business officer and promoted Scott Lauder to chief technology officer. Last fall, Gemini raised $42 million in Series A financing … Continue reading “Gemini Therapeutics Names Sandra Rojas-Caro Chief Medical Officer”
Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More
Biotech financing is a cyclical thing. Two years ago, the IPO window was unlatched but a number of companies ended up withdrawing their stock offerings. Others that pushed their IPOs through couldn’t sell shares at the price they wanted. This year, the IPO window is wide open. A total of 93 IPOs have priced as … Continue reading “Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More”